WHO
REGULATORY UPDATE
1st Invitation to manufacturers of medicinal products for treatment of substance use disorders, to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Unit
Published: 7/10/2026Detected: 5/25/2026
Summary preview
Launches the first WHO Expression of Interest (EOI) for manufacturers to apply for WHO Prequalification product evaluation for selected medicines used to treat opioid dependence and prevent opioid overdose.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountpsychiatry
manufacturing
quality
clinical
safety
labeling
#WHO prequalification
#expression of interest (EOI)
#opioid dependence
#overdose prevention
#methadone
Official Source Document Source Verified
Access the original document directly from WHO.
More from WHO
- New Deadline for Submission: Request for Quotations (RFQ) from interested Notified Bodies - WHO Prequalification Assessment for Medical Devices10/2/2026
- PQT/AMD newsletter - Q3 2026, Issue 54 is now available10/2/2026
- PQ Webinar: Launch of WHO Prequalification of Medical Devices10/2/2026
- New EUL listing10/2/2026
- Prequalification of In Vitro Diagnostics: Scope Expansion10/2/2026